Actinium Pharmaceuticals
ATNM
38 hedge funds and large institutions have $9.37M invested in Actinium Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 9 closing their positions.
284% more call options, than puts
Call options by funds: $5M | Put options by funds: $1.3M
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
0.7% less ownership
Funds ownership: 8.98% → 8.28% (-0.7%)
10% less funds holding
Funds holding: 42 → 38 (-4)
18% less capital invested
Capital invested by funds: $11.5M → $9.37M (-$2.12M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$187K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$130K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$102K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$72.1K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$60.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$386K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$341K |
| 3 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$163K |
| 4 |
DLG
Daniel L. Goodwin
|
-$60K |
| 5 |
Morgan Stanley
New York
|
-$53.5K |
ATNM Hedge Fund Activity: Q1 2022 in Review
38 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2022, worth a combined $9.37M — down 18% from $11.5M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ATNM and 5 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 12 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $187K. The largest seller was Sabby Management, exiting entirely with an estimated $386K sold.
- 38 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2022, down from 42 in Q4 2021.
- Funds reported $9.37M of Actinium Pharmaceuticals stock for Q1 2022, down 18% quarter-over-quarter.
- 5 funds opened new Actinium Pharmaceuticals positions in Q1 2022 and 9 closed out, a net change of -4 holders.
- The largest Actinium Pharmaceuticals buyer in Q1 2022 was Susquehanna International Group, an estimated $187K added.
- The largest Actinium Pharmaceuticals seller in Q1 2022 was Sabby Management, an estimated $386K sold.
Based on aggregated 13F filings for Q1 2022.